Utente:OppidumNissenae/Sandbox020: differenze tra le versioni

Versione delle 18:30, 26 apr 2021

Versione delle 18:31, 26 apr 2021

Riga 4:

{{Disclaimer|medico}}

[[File:Decision Tree for Diagnosing and Ruling Out VIPIT.png|thumb|Albero decisionale per la conferma della diagnosi di VIPIT]]

Gli '''eventi tromboembolici post-vaccinazione''' (in [[lingua inglese|inglese]]: '''VIPIT''', [[acronimo]] di '''''vaccine-induced prothrombotic immune thrombocytopenia''''',<ref name="pmid33822348"/> tradotto come '''trombocitopenia protrombotica immunitaria indotta da vaccino,''' chiamata anche '''''vaccine-induced thrombocytopenia and thrombosis''''' o '''VITT''';<ref name="MedPage Today 2021">{{cite web | title=From VIPIT to VITT: Thrombosis and COVID Vaccines | website=MedPage Today | date=2021-04-09 | url=https://www.medpagetoday.com/special-reports/exclusives/92022 | access-date=2021-04-11}}</ref> va distinta dalla '''coagulopatia indotta da COVID-19''' (CIC)<ref name="Hadid Kafri Al-Katib 2020 p=100761"/><ref name="pmid33851389">{{cite journal | vauthors = von Hundelshausen P, Lorenz R, Siess W, Weber C | title = Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors | journal = Thromb Haemost | volume = | issue = | pages = | date = April 2021 | pmid = 33851389 | doi = 10.1055/a-1481-3039 | url = | issn = }}</ref> va distinta dalla '''coagulopatia indotta da COVID-19''' (CIC)<ref name="Hadid Kafri Al-Katib 2020 p=100761"/> sono eventi [[Trombosi|trombotici]] rari osservati in un numero molto limitato di persone che hanno ricevuto in precedenza il [[Vaccino AstraZeneca anti COVID-19 ]] e il [[Vaccino anti COVID-19 Johnson & Johnson]].<ref name="ema28mar">{{Cita web|url=https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf|dataaccesso=2021-03-31}}</ref><ref name="PHA-Canada March">{{Cita news|nome=Agence de la santé publique du Canada|cognome=Public Health Agency of Canada|url=https://www.canada.ca/en/public-health/news/2021/03/use-of-astrazeneca-covid-19-vaccine.html|titolo=Use of AstraZeneca COVID-19 vaccine in younger adults|data=29 March 2021|accesso=2 April 2021}}</ref><ref name="European Medicines Agency 2021"/>

Questi eventi si manifestano con [[fisiopatologia|caratteristiche fisiopatologiche]] simili alla [[trombocitopenia indotta da eparina]].<ref name="pmid33822348">{{cite journal | vauthors = Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, Korte W, Scharf RE, Pötzsch B, Greinacher A | title = Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH | journal = Hamostaseologie | volume = | issue = | pages = | date = April 2021 | pmid = 33822348 | doi = 10.1055/a-1469-7481 | url = | issn = }}</ref>